Semaglutide
Semaglutide (Ozempic/Wegovy)
The most well-known GLP-1 receptor agonist, approved for both diabetes and obesity. Backed by extensive clinical data and the largest user base of any weight loss medication.
How Semaglutide Works
Semaglutide is a long-acting GLP-1 receptor agonist with 94% structural homology to native human GLP-1 but engineered for extended duration. It works by binding to GLP-1 receptors in the pancreas to enhance glucose-dependent insulin secretion, in the stomach to delay gastric emptying, and in the hypothalamus to reduce appetite and food intake. The albumin binding and fatty acid acylation give it a half-life of approximately 7 days, enabling once-weekly dosing. Its central appetite-suppressing effect is the primary driver of the significant weight loss observed in clinical trials.
📊 Evidence by Outcome
STEP trials demonstrated 15-17% weight loss. Largest body of evidence for any weight loss drug.
20 studies • Consistency: High • Effect: Large
SELECT trial showed 20% reduction in major cardiovascular events independent of diabetes status.
8 studies • Consistency: High • Effect: Large
Gold standard for type 2 diabetes management.
15 studies • Consistency: High • Effect: Large
Key Research
Peer-Reviewed Evidence • 3 Citations
Once-weekly semaglutide in adults with overweight or obesity (STEP 1)
Wilding JPH et al.•N Engl J Med•2021•PMID: 33567185
Key Finding: Semaglutide 2.4mg achieved 14.9% mean body weight reduction vs 2.4% with placebo over 68 weeks in non-diabetic adults.
View on PubMedSemaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)
Marso SP et al.•N Engl J Med•2016•PMID: 27633186
Key Finding: Semaglutide reduced major cardiovascular events by 26% in type 2 diabetes patients, establishing cardioprotective benefits.
View on PubMedOral semaglutide versus empagliflozin in patients with type 2 diabetes (PIONEER 2)
Rodbard HW et al.•Diabetes Care•2019•PMID: 31530667
Key Finding: Oral semaglutide provided superior HbA1c reduction compared to empagliflozin, demonstrating efficacy of oral GLP-1 delivery.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
Side Effects & Safety
Interactions & Contraindications
Drug Interactions
- •Insulin and sulfonylureas — dose reduction required to avoid hypoglycemia
- •Oral medications — delayed gastric emptying can alter absorption (particularly levothyroxine, oral contraceptives, antibiotics)
- •Warfarin — INR monitoring recommended during initiation
- •Oral contraceptives — consider non-oral alternatives during dose escalation
- •Acetaminophen — delayed absorption (Cmax reduced by 12%, Tmax delayed by 1 hour)
Supplement Interactions
- •Oral supplements may have delayed absorption
- •Electrolyte supplementation recommended with significant GI losses
- •Protein supplementation strongly recommended to preserve lean mass
- •B12 supplementation may be needed with long-term use (reduced absorption)
Food & Timing
- •Eat smaller, more frequent meals
- •Avoid high-fat, greasy, and fried foods
- •Prioritize protein at every meal (target 1.2-1.6g/kg/day)
- •Stay well hydrated (2-3 liters/day minimum)
- •Limit alcohol (increased pancreatitis risk and reduced tolerance)
Who Should Avoid
- •Personal or family history of medullary thyroid carcinoma (MTC)
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- •History of pancreatitis
- •Pregnancy (Category X — discontinue at least 2 months before planned conception)
- •Breastfeeding
- •Type 1 diabetes
- •Severe gastroparesis
- •Known hypersensitivity to semaglutide or any excipients
- •Severe renal impairment (use with caution; monitor closely)
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
AED 1,200-3,000/month
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Frequently Asked Questions
Yes, Semaglutide is widely available in the UAE. Ozempic (for diabetes) and Wegovy (for weight management) are both registered and available through clinics and pharmacies. It is one of the most prescribed GLP-1 medications in the region. Demand is high and periodic shortages have occurred.
Appetite suppression is usually felt within the first 1-2 weeks. Measurable weight loss typically begins at 4-8 weeks as the dose escalates to therapeutic levels. Peak weight loss in the STEP trials was at 68 weeks, with the majority occurring in the first 32 weeks.
They are the same molecule (semaglutide) from the same manufacturer (Novo Nordisk). Ozempic is approved for type 2 diabetes at doses up to 2mg/week. Wegovy is approved for weight management at the higher 2.4mg/week dose. The medication and injection device are identical aside from dosing.
Rapid weight loss from any cause can lead to facial volume loss and muscle loss. In STEP trials, approximately 30-40% of weight lost was lean mass. Resistance training (2-3x/week), adequate protein intake (1.2-1.6g/kg), and gradual dose escalation can minimize these effects. Some clinics combine semaglutide with peptides or testosterone to preserve muscle.
Yes, oral semaglutide (Rybelsus) is available for type 2 diabetes, though at lower doses than injectable Wegovy. It must be taken on an empty stomach with no more than 120ml of water, and you must wait at least 30 minutes before eating. The injectable form is generally considered more effective for weight loss at equivalent doses.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.